Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Allogene Therapeutics (ALLO) Assets Average: 2019-2025

Historic Assets Average for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to $455.2 million.

  • Allogene Therapeutics' Assets Average fell 26.35% to $455.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $455.2 million, marking a year-over-year decrease of 26.35%. This contributed to the annual value of $595.8 million for FY2024, which is 18.63% down from last year.
  • Per Allogene Therapeutics' latest filing, its Assets Average stood at $455.2 million for Q3 2025, which was down 6.97% from $489.3 million recorded in Q2 2025.
  • In the past 5 years, Allogene Therapeutics' Assets Average ranged from a high of $1.2 billion in Q1 2021 and a low of $455.2 million during Q3 2025.
  • Moreover, its 3-year median value for Assets Average was $616.6 million (2024), whereas its average is $623.6 million.
  • Its Assets Average has fluctuated over the past 5 years, first skyrocketed by 71.15% in 2021, then dropped by 26.35% in 2025.
  • Quarterly analysis of 5 years shows Allogene Therapeutics' Assets Average stood at $1.1 billion in 2021, then declined by 19.44% to $858.0 million in 2022, then fell by 20.97% to $678.1 million in 2023, then decreased by 16.10% to $568.9 million in 2024, then declined by 26.35% to $455.2 million in 2025.
  • Its Assets Average stands at $455.2 million for Q3 2025, versus $489.3 million for Q2 2025 and $528.3 million for Q1 2025.